BLUETTI
25.11.2022 12:22:36 CET | Business Wire | Press release
Electricity demand is predicted to grow rapidly as winter is coming soon. Under the rules introduced by Swiss government ordinance, buildings with gas heating systems can only warm rooms up to 19°C. However, it’s not just Switzerland bearing the brunt of the energy crisis. Europe’s largest economy recently announced a winter gas surcharge would come into effect in October. Many countries are gradually taking drastic measures to respond to the surging energy demand.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20221124005140/en/
Secure your home with BLUETTI backup power this winter. (Photo: Business Wire)
In this case, why not consider powering via a smarter, greener, and more affordable way? The upcoming launch of BLUETTI EP600 is undeniable a big moment for building a whole-house backup power system. It’s a long-anticipated model to help citizens realize power independence with ease and be well-prepared for the unexpected without any fuss.
EP600 is a modular ESS (Energy Storage System) that provides a one-stop solution for every family to alleviate energy shortages. It is packed with a 6.000VA bi-directional inverter for AC input and output, delivering 230/400V AC power to run almost any household appliance.
B500 expansion battery features 4.960Wh LFP battery cells for a 10 years lifespan. Every EP600 supports up to 16*B500 for a 79,3kWh capacity, sufficient to cover all power needs at home even in the coldest winter!
How to cushion soaring energy bills through EP600 ESS?
At sunrise, EP600 captures and converts the sunlight into ready-to-use solar energy. It’s recommended to use solar and the grid when energy price is low. Meanwhile, the excess can be stored for later use or even sold to power companies to earn commissions. Utility power costs a pretty penny in the afternoon when there’s most sunlight in the daytime. By connecting with solar panels, EP600 accepts up to 6.000W solar input, so fully charging an EP600+2*B500 combo only takes about 2,2 hours!
During peak hours (generally from 4PM to 9PM), EP600 can take the place of the grid and become the only power source of all appliances, making it an effective approach to avoiding higher electricity bills in the long run.
BLUETTI officially released EP600 & B500 on November 10, 4:00 PM (Berlin time) in specific countries, including Germany, Italy, French, Spain, Netherland.
The early bird price of the EP600 & 2*B500 combo is $8.999 till December 31, and It is expected to ship by the end of November after pre-ordering.
About BLUETTI
With over 10 years of industry experience, BLUETTI has tried to stay true to a sustainable future through green energy storage solutions for both indoor and outdoor use while delivering an exceptional eco-friendly experience for everyone and the world. BLUETTI is making its presence in 70+ countries and is trusted by millions of customers across the globe. For more information, please visit BLUETTI online at https://www.bluettipower.eu/.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20221124005140/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Echodyne Opens New Manufacturing Facility to Meet Surging Global Demand for Advanced MESA® Radar9.7.2026 15:00:00 CEST | Press release
New Washington State facility provides capacity to manufacture more than 30,000 radars annually, strengthening the U.S. defense industrial base As governments around the world accelerate investment in counter-unmanned aircraft systems (C-UAS) and short-range air defense, Echodyne today announced the opening of a new advanced radar manufacturing facility in Washington State, significantly expanding its manufacturing capacity to meet rapidly growing demand from U.S. and allied customers. With millions of drones manufactured and used by both sides in the Russian War in Ukraine, the need for enhanced safety for defense, national security, and critical infrastructure assets grows with every successful strike and interception. The low cost and high utility of drones dramatically alters the need for safety and security sensors. And as the low altitude economy takes off, hundreds of thousands of drones will perform a range of life-saving and commercial missions, requiring a sensor infrastructu
Orca Security Report: 99.9% of Fixable AI Vulnerabilities Remain Unpatched as AI Moves Into Production9.7.2026 15:00:00 CEST | Press release
Analysis of more than 1,200 production cloud environments provides a first-hand view into how organizations are embedding AI into business-critical workflows, exposing new security risks that traditional controls weren't built to address. Orca Security, a leader in cloud and AI security, today released its 2026 State of AI Security Report, offering a first-hand view into how AI is being deployed across more than 1,200 production cloud environments. The findings show AI is no longer limited to isolated pilots or developer experiments. Organizations are embedding AI into production applications, cloud services, and autonomous workflows faster than security programs can adapt. More than half (56%) of organizations have already deployed AI agents into production, while 51% use AI to build custom applications. At the same time, Orca found that 81% of organizations run vulnerable AI packages, and 99.9% of fixable AI vulnerabilities remain unpatched, highlighting how quickly AI has become ope
Viz.ai Expands into Neurodegenerative Disease with Cortechs.ai Collaboration9.7.2026 15:00:00 CEST | Press release
Cortechs.ai and Viz.ai partner to tackle multiple sclerosis and other neurodegenerative diseases across Viz.ai's health system network Viz.ai, the leader in AI-powered disease detection and intelligent care coordination, today announced a collaboration with Cortechs.ai, a global leader in neuroimaging and quantitative analysis solutions, to integrate Cortechs.ai's NeuroQuant and NeuroQuant MS suite into the Viz.ai platform, expanding access to quantitative neuroimaging for hospitals and health systems across the U.S. This partnership marks Viz.ai's expansion into neurodegenerative disease, growing Viz Neuro Suite beyond its already market-leading neuro offerings. The collaboration will begin with a focus on multiple sclerosis (MS), integrating quantitative MRI analysis from NeuroQuant MS directly into Viz.ai's care coordination workflow, giving clinicians both the quantitative precision and the coordination infrastructure needed to identify and manage MS patients at scale. “Viz.ai's co
SCP Standard Capital Partners AG: Fabian Becker Appointed Chairman of the Management Board and CEO9.7.2026 14:51:00 CEST | Press release
The Supervisory Board of SCP Standard Capital Partners AG (WKN: A12UPJ | ISIN: DE000A12UPJ7 | XETRA ticker: CAP) resolved today to appoint Mr. Fabian Becker as Chairman of the Management Board and Chief Executive Officer (CEO), effective as of 9 July 2026. Ms. Stephanie Schettler-Köhler will remain a member of the Management Board and will assume the role of Chief Operating Officer (COO). View source version on businesswire.com: https://www.businesswire.com/news/home/20260709982268/en/
Teva and Polpharma Biologics Announce Global Licensing Agreement for a Biosimilar Candidate to Ocrevus® (ocrelizumab) for Multiple Sclerosis9.7.2026 14:45:00 CEST | Press release
Teva secures exclusive global rights to commercialize Polpharma Biologics’ biosimilar candidate to Ocrevus® (ocrelizumab), including both intravenous and subcutaneous formulations.Agreement advances Teva’s Pivot to Growth strategy by expanding its biosimilars pipeline through strategic collaborations.Agreement reflects both companies’ commitment to broadening access to biologic medicines. Teva Pharmaceuticals International GmbH, a subsidiary of Teva Pharmaceutical Industries Ltd (NYSE: and TASE: TEVA) and Polpharma Biologics International AG today announced a global licensing agreement granting Teva exclusive rights to commercialize both formulations of Polpharma Biologics’ proposed biosimilar to Ocrevus®1 (ocrelizumab), upon regulatory approval. This strategic agreement is expected to combine Polpharma Biologics’ proven biosimilar development expertise with Teva’s commercial footprint and capabilities. This press release features multimedia. View the full release here: https://www.bus
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom